<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>De Novo Design of SIK3 Inhibitors via Feedback-Driven Fine-Tuning of Seq2Seq-VAE - Health AI Hub</title>
    <meta name="description" content="This paper presents a novel generative AI pipeline, employing a sequence-to-sequence Variational Autoencoder (Seq2Seq-VAE) guided by Active Learning (AL), for t">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>De Novo Design of SIK3 Inhibitors via Feedback-Driven Fine-Tuning of Seq2Seq-VAE</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.06930v1" target="_blank">2511.06930v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-10
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> ShahZeb Khan, Chiara Pallara, Barbara Monti, Alexis Molina
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.BM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.06930v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.06930v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper presents a novel generative AI pipeline, employing a sequence-to-sequence Variational Autoencoder (Seq2Seq-VAE) guided by Active Learning (AL), for the *de novo* design of Salt-Inducible Kinase 3 (SIK3) inhibitors. The method iteratively optimizes molecular properties and predicted binding affinity towards SIK3, successfully generating high-affinity, drug-like small molecules relevant for Alzheimer's disease with minimal data requirements.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly medically relevant as it addresses the critical unmet need for effective disease-modifying treatments for Alzheimer's disease by identifying and designing inhibitors for a novel therapeutic target, SIK3. It offers a powerful, data-efficient computational strategy to accelerate early-stage drug discovery, potentially leading to new therapies for AD.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper applies generative AI (Seq2Seq-VAE model with Active Learning) for de novo drug design. Specifically, it uses this AI framework to identify and optimize novel small molecule inhibitors for Salt-Inducible Kinase 3 (SIK3), which is a identified therapeutic target for Alzheimer's disease. This represents an AI application for rational drug discovery and lead compound identification in medicine.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Alzheimer's disease (AD) lacks effective disease-modifying therapies, with circadian clock kinases like SIK3 identified as promising therapeutic targets due to their role in AD pathophysiology.</li>
                    
                    <li>The research utilizes a sequence-to-sequence Variational Autoencoder (Seq2Seq-VAE) as the generative AI model for *de novo* molecular design, optimized by an Active Learning (AL) approach.</li>
                    
                    <li>The core methodology involves a two-step feedback-driven optimization framework: an 'inner loop' that iteratively improves physicochemical properties, drug-likeness, and synthesizability, and an 'outer loop' that steers the latent space towards generating high-affinity ligands for SIK3.</li>
                    
                    <li>A key advantage of this active learning approach is its ability to optimize molecular generation without requiring large labeled datasets, making it particularly well-suited for early-stage drug discovery targeting under-explored proteins.</li>
                    
                    <li>The model successfully converged, demonstrating the generation of SIK3-specific small molecules that possess desired drug-like properties and high predicted binding affinity for the target.</li>
                    
                    <li>This work provides a scalable solution to the molecular design bottleneck in drug discovery, as the generative AI + AL pipeline can be extended to other protein targets with minimal modifications.</li>
                    
                    <li>The approach aims to accelerate the rational design and discovery of novel therapeutic candidates for complex neurodegenerative disorders like Alzheimer's disease.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study employed a pre-trained sequence-to-sequence Variational Autoencoder (Seq2Seq-VAE) model, which was iteratively guided and optimized using an Active Learning (AL) approach. This AL framework incorporated a two-step feedback-driven process: an 'inner loop' focusing on improving physicochemical properties, drug-likeness, and synthesizability of generated molecules, followed by an 'outer loop' designed to steer the VAE's latent space towards generating high-affinity ligands specifically for Salt-Inducible Kinase 3 (SIK3). This optimization strategy was designed to operate effectively without the need for extensive labeled datasets.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The generative AI model, iteratively optimized through the Active Learning framework, successfully converged to design SIK3-specific small molecules. These newly generated compounds were shown to possess desirable physiochemical properties, exhibit drug-likeness, are predicted to be synthesizable, and demonstrate high predicted binding affinity for the SIK3 protein.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This work has the potential to significantly impact clinical translation by accelerating the early-stage discovery and design of novel therapeutic compounds for Alzheimer's disease, specifically targeting SIK3. By providing a scalable, data-efficient computational platform for molecular design, it could substantially reduce the time, cost, and experimental burden associated with identifying promising drug candidates, thereby expediting the development of new treatment options for AD and potentially other challenging diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the proposed methodology. However, it highlights a strength ‚Äì the ability to circumvent the need for large labeled datasets ‚Äì which is often a significant limitation in early-stage drug discovery. While the approach generated molecules with 'high binding affinity,' this is implied to be computationally predicted, and experimental validation of affinity and SIK3 inhibition in biological systems would be a necessary subsequent step not covered by the abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The authors suggest that their generative AI combined with Active Learning pipeline for rational drug discovery is highly extensible. They propose it can be applied to other protein targets with minimal modifications, indicating its potential as a scalable solution to address the broader molecular design bottleneck encountered in drug development across various therapeutic areas.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurodegenerative Diseases</span>
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Neuropharmacology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Circadian Biology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Alzheimer's Disease</span>
                    
                    <span class="tag tag-keyword">Salt-Inducible Kinase 3 (SIK3)</span>
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Active Learning</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Molecular Design</span>
                    
                    <span class="tag tag-keyword">Variational Autoencoder</span>
                    
                    <span class="tag tag-keyword">Circadian Rhythm</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Alzheimers disease (AD), a progressive neuro-degenerative disorder, currently
lacks effective therapeutic strategies that can modify disease progression.
Recent studies have highlighted the circadian rhythm critical role in AD
pathophysiology, implicating circadian clock kinases, such as the
Salt-Inducible Kinase 3 (SIK3), as promising therapeutic target. Generative AI
models have surpassed traditional methods of drug discovery, untapping the vast
unexplored chemical space of drug-like molecules. We present a
sequence-to-sequence Variational Autoencoder (Seq2Seq-VAE) model guided by an
Active Learning (AL) approach to optimize molecular generation. Our pipeline
iteratively guided a pre-trained Seq2Seq-VAE model towards the pharmacological
landscape relevant to SIK3 using a two-step framework, an inner loop that
iteratively improves physiochemical properties profile, drug likeliness and
synthesizability, followed by an outer loop that steer the latent space towards
high-affinity ligands for SIK3. Our approach introduces feedback-driven
optimization without requiring large labeled datasets, making it particularly
suited for early-stage drug discovery in under-explored therapeutic targets.
Our results demonstrate the models convergence toward SIK3-specific small
molecules with desired properties and high binding affinity. This work
highlights the use of generative AI combined with AL for rational drug
discovery that can be extended to other protein targets with minimal
modifications, offering a scalable solution to the molecular design bottleneck
in drug design.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>